Hydromorphone-OROS formulation

Bibliography

• Van den Bueken-van Everdingen MHJ, de Rijke JM, Kessels AG, Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49
   PubMedGoogle Scholar
• Sorenson HT, Rasmussen HH, Moller-Petersen JF, Epidemiology of pain requiring strong analgesics outside hospital in a geographically defined population in Denmark. Dan Med Bull 1992;39:464-7
   PubMedGoogle Scholar
• Collett BJ. Chronic opioid therapy for non-cancer pain. Br J Anaesth 2001;87:133-43
   PubMed Web of Science ®Google Scholar
• Bell JR. Austrialian trends in opioid prescribing for non-cancer pain 1986 – 1996. Med J Aust 1997;167:26-9
   PubMed Web of Science ®Google Scholar
• Coniam SW. Prescribing opioids for chronic pain in non-malignant disease. In: Tywcross RG, editor, The Edinburgh Symposium on Pain Control and Medical Education. Royal Society of Medicine International Congress and Symposium Series. Royal Society of Medicine, London; 1989. p. 205-10, 149
   Google Scholar
• Gardner-Nix J, Mercadante S. The role of OROS hydromorphone in the management of cancer pain. Pain Pract 2010;10:72-7
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciulloz GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Maetzke S, Haakana S, Transdermal fentanyl in cachectic cancer patients. Pain 2009;144:218-22
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boeger RH, Budd K, Opioids in the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Crook, J, Rideout E, Browne G. The prevalence of pain complaints in a general population. Pain 1984;18:299-314
   PubMed Web of Science ®Google Scholar
• Helme RD, Gibson SJ. The epidemiology of pain in elderly people. Clin Geriatr Med 2001;17:417-31
   PubMed Web of Science ®Google Scholar
• Barberger-Gateau P, Chaslerie A, Dartigues J, Health measures correlates in a French elderly community population: the PAQUID study. J Gerontol 1992;47:S88-95
   PubMedGoogle Scholar
• Hydromorphone Prescribing Information. Available from: http://www.purdue.ca/pdf/2008-08-08%20Dilaudid%20PI%20for%20Mod-Indication%20only_ENG%20Mktg%20FINAL.pdf [Last accessed 3 January 2010]
   Google Scholar
• Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29:S57-66
   PubMed Web of Science ®Google Scholar
• Turgeon J, Groening R, Sathyan G, The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv 2010;7:137-44
   PubMed Web of Science ®Google Scholar
• Hale M, Rauck R, Khan A, A randomized, double-blind study of OROS hydromorphone extended release (ER) compared to placebo in opioid-tolerant patients with moderate to severe chronic low back pain. Poster presented at the 28th Annual Scientific Meeting of the American Pain Society, 6 – 9 May 2009, San Diego, CA, USA
   Google Scholar
• Wallace M, Thipphawong J. Open label extension study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone extended release in patients with chronic low back pain. Poster presented at the 28th Annual Scientific Meeting of the American Pain Society, 6 – 9 May 2009, San Diego, CA, USA
   Google Scholar
• Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29:874-88
   PubMed Web of Science ®Google Scholar
• Wallace M, Rauck RL, Moulin D, Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract 2007;61:1671-6
   PubMed Web of Science ®Google Scholar
• Wallace M, Rauck RL, Moulin D, Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2008;36:343-52
   PubMed Web of Science ®Google Scholar
• Wallace M, Moulin DE, Rauck RL, Long term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5:97-105
   PubMedGoogle Scholar
• Hanna M, Thipphawong J, 118 Study Group. A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008;7:17
   PubMedGoogle Scholar
• Wallace M, Skowronski R, Khanna S, Efficacy and safety evaluation of once daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007;23:981-9
   PubMed Web of Science ®Google Scholar
• Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain. BMC Palliat Care 2009;15:14
   Google Scholar
• DEA Website Information. Drugs and chemicals of concern: hydromorphone. Available from: www.deadiversion.usdoj.gov/drugs_concern/hydromorphone.htm [Last accessed 3 January 2010]
   Google Scholar
• Sathyan, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24 hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008;24:297-305
   PubMed Web of Science ®Google Scholar
• Shram MJ, Thipphawong J, Romach M, Sellers EM. Assessing the abuse potential of an oral osmotic-controlled extended release (OROS) hydromorphone compared to immediate release hydromorphone. Poster presented at the 28th Annual Scientific Meeting of the American Pain Society, 6 – 9 May 2009, San Diego, CA, USA
   Google Scholar
• Medical News. FDA endorses Covidien's REMS program for EXALGO tablets. Available from: http://www.news-medical.net/news/20090924/FDA-endorses-Covidiens-REMS-program-for-EXALGO-tablets.aspx [Last accessed 3 January 2010]
   Google Scholar
• Combinator Public Announcement. Available from: http://www.combinatorx.com/products_pain_exalgo.php [Last accessed 3 January 2010]
   Google Scholar
• Medical News Today Announcement. Available from: http://www.medicalnewstoday.com/articles/171870.php [Last accessed 3 January 2010]
   Google Scholar